Efficacy of Mabthera (anti CD20 Ab) in patients with relapsed/progressed Hairy cell leukemia.

被引：0
|
作者：
Lauria, F
Lenoci, M
Annino, L
Raspadori, D
Marotta, G
Bocchia, M
Gentili, S
La Manda, M
Marconcini, S
Zinzani, PL
机构：
[1] Univ Siena, I-53100 Siena, Italy
[2] Univ La Sapienza, Rome, Italy
[3] Seragnoli, Bologna, Italy
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
592
引用
收藏
页码：138A / 138A
页数：1
相关论文
共 50 条
  • [1] Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia
    Lauria, F
    Lenoci, M
    Annino, L
    Raspadori, D
    Marotta, G
    Bocchia, M
    Forconi, F
    Gentili, S
    La Manda, M
    Marconcini, S
    Tozzi, M
    Baldini, L
    Zinzani, PL
    Foà, R
    HAEMATOLOGICA, 2001, 86 (10) : 1046 - 1050
  • [2] Efficacy of rituximab in hairy cell leukemia.
    Kokoris, Styliani I.
    Angelopoulou, Maria K.
    Galani, Zacharoula I.
    Anargyrou, Konstantinos
    Sachanas, Sotirios
    Vassilakopoulos, Theodoros P.
    Siakantaris, Marina P.
    Kontopidou, Flora N.
    Dimitriadou, Evangelia M.
    Dimopoulou, Maria N.
    Tsaftaridis, Panayiotis
    Plata, Eleni
    Kalpadakis, Christina
    Kyrtsonis, Marie. -Christine
    Panayiotidis, Panayiotis
    Pangali, Gerassimos A.
    BLOOD, 2006, 108 (11) : 262B - 262B
  • [3] The expression of CD20 in adult acute lymphoblastic leukemia.
    Jagoda, K
    Stella-Holowiecka, B
    Giebel, S
    Krawczyk, M
    Wozniczka, K
    Goracy, A
    Lewandowski, K
    Krawczynska, A
    Balana-Nowak, A
    Wozniak, J
    Holowiecki, J
    BLOOD, 2003, 102 (11) : 237B - 238B
  • [4] Loss of CD20 expression following treatment with anti-CD20 monoclonal antibody in chronic lymphocytic leukemia.
    Savage, KJ
    Weng, AP
    Kutok, JL
    Pinkus, G
    Gribben, JG
    BLOOD, 2002, 100 (11) : 364B - 364B
  • [5] PHARMACOKINETICS OF MOXETUMOMAB PASUDOTOX, AN INVESTIGATIONAL IMMUNOTOXIN TARGETING CD22, IN PATIENTS WITH RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA.
    Wang, B.
    Chang, L.
    Kreitman, R. J.
    Ibrahim, R.
    Goswami, T.
    Pastan, I.
    Liang, M.
    Roskos, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S36 - S37
  • [6] Level of CD20 expression and disease activity in chronic lymphocytic leukemia.
    Benke, SM
    Sheridan, D
    BLOOD, 2003, 102 (11) : 226B - 226B
  • [7] CD52 and CD20 as potential targets for anti-leukemic immunotherapy in adult acute lymphoblastic leukemia.
    Jagoda, K
    Giebel, S
    Stella-Holowiecka, B
    Krawczyk-Kulis, M
    Holowiecki, J
    BLOOD, 2004, 104 (11) : 184B - 185B
  • [8] Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.
    Kreitman, Robert J.
    Stetler-Stevenson, Maryalice
    Yuan, Constance
    Wang, Hao-Wei
    Zhou, Hong
    Raffeld, Mark
    Xi, Liqiang
    Arons, Evgeny
    Feurtado, Julie
    James-Echenique, Lacey
    Braylan, Raul
    Calvo, Katherine R.
    Maric, Irina
    Dulau, Alina
    Pastan, Ira
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Patients with relapsed/refractory hairy-cell leukemia
    Paillassa, Jerome
    Troussard, Xavier
    CANCER REPORTS, 2022, 5 (03)
  • [10] Monoclonal anti CD20 antibody rituximab (Mabthera) in the treatment of autoimmune cyclical neutropenia - case report
    Georgievski, B
    Stojanovic, A
    Sijanoski, N
    Cevreska, L
    Stavric, SG
    Stojanoski, Z
    Panovska, I
    Pivkova, A
    Trajkova, S
    Balkanov, S
    Karanfilski, O
    BONE MARROW TRANSPLANTATION, 2005, 35 : S380 - S381
12345